"The results of this Phase II trial, showing safety and immunogenicity of HER-Vaxx in patients with HER2-overexpressing GC suggests a potential pathway for HER2/HER-Vaxx-based vaccines as a treatment modality in HER2-overexpressing cancers."
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.003(27.3%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.1¢ | $295.4K | 24.07M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 4870164 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 10482572 | 43 |
View Market Depth
| Last trade - 12.03pm 27/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |